Toward defining the preclinical stages of Alzheimer's disease

Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Reisa A. Sperling, Paul S. Aisen, Laurel A Beckett, David A. Bennett, Suzanne Craft, Anne M. Fagan, Takeshi Iwatsubo, Clifford R. Jack, Jeffrey Kaye, Thomas J. Montine, Denise C. Park, Eric M. Reiman, Christopher C. Rowe, Eric Siemers, Yaakov Stern, Kristine Yaffe, Maria C. Carrillo, Bill Thies, Marcelle Morrison-Bogorad, Molly V. Wagster & 1 others Creighton H. Phelps

Research output: Contribution to journalArticle

3068 Citations (Scopus)

Abstract

The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious.

Original languageEnglish (US)
Pages (from-to)280-292
Number of pages13
JournalAlzheimer's and Dementia
Volume7
Issue number3
DOIs
StatePublished - May 2011

Fingerprint

National Institute on Aging (U.S.)
Alzheimer Disease
Guidelines
Research
Cognition
Biomarkers

Keywords

  • Amyloid
  • Biomarker
  • Neurodegeneration
  • Preclinical Alzheimer's disease
  • Prevention

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Toward defining the preclinical stages of Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. / Sperling, Reisa A.; Aisen, Paul S.; Beckett, Laurel A; Bennett, David A.; Craft, Suzanne; Fagan, Anne M.; Iwatsubo, Takeshi; Jack, Clifford R.; Kaye, Jeffrey; Montine, Thomas J.; Park, Denise C.; Reiman, Eric M.; Rowe, Christopher C.; Siemers, Eric; Stern, Yaakov; Yaffe, Kristine; Carrillo, Maria C.; Thies, Bill; Morrison-Bogorad, Marcelle; Wagster, Molly V.; Phelps, Creighton H.

In: Alzheimer's and Dementia, Vol. 7, No. 3, 05.2011, p. 280-292.

Research output: Contribution to journalArticle

Sperling, RA, Aisen, PS, Beckett, LA, Bennett, DA, Craft, S, Fagan, AM, Iwatsubo, T, Jack, CR, Kaye, J, Montine, TJ, Park, DC, Reiman, EM, Rowe, CC, Siemers, E, Stern, Y, Yaffe, K, Carrillo, MC, Thies, B, Morrison-Bogorad, M, Wagster, MV & Phelps, CH 2011, 'Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease', Alzheimer's and Dementia, vol. 7, no. 3, pp. 280-292. https://doi.org/10.1016/j.jalz.2011.03.003
Sperling, Reisa A. ; Aisen, Paul S. ; Beckett, Laurel A ; Bennett, David A. ; Craft, Suzanne ; Fagan, Anne M. ; Iwatsubo, Takeshi ; Jack, Clifford R. ; Kaye, Jeffrey ; Montine, Thomas J. ; Park, Denise C. ; Reiman, Eric M. ; Rowe, Christopher C. ; Siemers, Eric ; Stern, Yaakov ; Yaffe, Kristine ; Carrillo, Maria C. ; Thies, Bill ; Morrison-Bogorad, Marcelle ; Wagster, Molly V. ; Phelps, Creighton H. / Toward defining the preclinical stages of Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. In: Alzheimer's and Dementia. 2011 ; Vol. 7, No. 3. pp. 280-292.
@article{35470599c8834fd4b5cbfaaa4f7b6d9e,
title = "Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease",
abstract = "The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long {"}preclinical{"} phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from {"}normal{"} cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious.",
keywords = "Amyloid, Biomarker, Neurodegeneration, Preclinical Alzheimer's disease, Prevention",
author = "Sperling, {Reisa A.} and Aisen, {Paul S.} and Beckett, {Laurel A} and Bennett, {David A.} and Suzanne Craft and Fagan, {Anne M.} and Takeshi Iwatsubo and Jack, {Clifford R.} and Jeffrey Kaye and Montine, {Thomas J.} and Park, {Denise C.} and Reiman, {Eric M.} and Rowe, {Christopher C.} and Eric Siemers and Yaakov Stern and Kristine Yaffe and Carrillo, {Maria C.} and Bill Thies and Marcelle Morrison-Bogorad and Wagster, {Molly V.} and Phelps, {Creighton H.}",
year = "2011",
month = "5",
doi = "10.1016/j.jalz.2011.03.003",
language = "English (US)",
volume = "7",
pages = "280--292",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Toward defining the preclinical stages of Alzheimer's disease

T2 - Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

AU - Sperling, Reisa A.

AU - Aisen, Paul S.

AU - Beckett, Laurel A

AU - Bennett, David A.

AU - Craft, Suzanne

AU - Fagan, Anne M.

AU - Iwatsubo, Takeshi

AU - Jack, Clifford R.

AU - Kaye, Jeffrey

AU - Montine, Thomas J.

AU - Park, Denise C.

AU - Reiman, Eric M.

AU - Rowe, Christopher C.

AU - Siemers, Eric

AU - Stern, Yaakov

AU - Yaffe, Kristine

AU - Carrillo, Maria C.

AU - Thies, Bill

AU - Morrison-Bogorad, Marcelle

AU - Wagster, Molly V.

AU - Phelps, Creighton H.

PY - 2011/5

Y1 - 2011/5

N2 - The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious.

AB - The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long "preclinical" phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from "normal" cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease-modifying therapies may be most efficacious.

KW - Amyloid

KW - Biomarker

KW - Neurodegeneration

KW - Preclinical Alzheimer's disease

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=79956098248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956098248&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2011.03.003

DO - 10.1016/j.jalz.2011.03.003

M3 - Article

VL - 7

SP - 280

EP - 292

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -